Fig. 2
From: Development of a novel BRCAness score that predicts response to PARP inhibitors
Association of BRCAness score with mutation load, intratumor heterogeneity, and BRCA1 mutation with DNA repair and MKI67 expression in breast cancer. A Bar plots of BRCA1 mutation rates by low or high BRCAness in the METABRIC and TCGA cohorts. Fisher’s exact test was used to calculate p-values. B Boxplots of mutation counts (per mega base) by low or high BRCAness groups in the GSE96058, METABRIC, and TCGA cohorts. C Boxplots of mutation-related scores; fraction altered, silent & non-silent mutation rate, SNV & indel neoantigens, intratumor heterogeneity, and HRD, by low or high BRCAness groups. D Boxplots of the DNA repair score and MKI67 gene expression by four groups (MH; BRCA1 mutation with high BRCAness, WH; BRCA1 wildtype with high BRCAness, ML; BRCA1 mutation with low BRCAness, and WL; BRCA1 wildtype with low BRCAness) in the TCGA (n = 17/336/10/706) and METABRIC (n = 25/603/12/1264) cohorts. The top tertile was used as a cutoff to divide high- from low- BRCAness groups. The Mann-Whitney U test and Kruskal-Wallis test were used to calculate p-values. SNV, single nucleotide variation